AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10197378 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole plus vitamins A, C and E, selenium and zinc
Number of subjects: 0
Study 10197378 — intervention group
Group type: COMPARATOR
Intervention: albendazole plus placebo
Number of subjects: 0
Study 7790550 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection flow: 4 ml/s (Protocol 3)
Number of subjects: 75
Study 7790550 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection flow: 4 ml/s (60 ml) + 2 ml/s (40 ml) (Protocol 2)
Number of subjects: 75
Study 7790550 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection flow: 2 ml/s (Protocol 1)
Number of subjects: 75
Study 2087407 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 0
Study 2087407 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 0
Study 387496 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline theophyllinate 400 mg
Number of subjects: 17
Study 387496 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 4 mg
Number of subjects: 17
Study 387496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31005677 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention (three face-to-face consultations and two telephone consultations)
Number of subjects: 20
Study 31005677 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention
Number of subjects: 20
Study 31005677 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study 28094472 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-hormone artificial pancreas
Number of subjects: 23
Study 28094472 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-hormone artificial pancreas
Number of subjects: 23
Study 28094472 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy (control)
Number of subjects: 23
Study 26313620 — intervention group
Group type: EXPERIMENTAL
Intervention: One Session Treatment (OST) with e-therapy homework maintenance program over 4 weeks
Number of subjects: 24
Study 26313620 — intervention group
Group type: COMPARATOR
Intervention: Baseline periods (no intervention)
Number of subjects: 24
Study 23358514 — intervention group
Group type: EXPERIMENTAL
Intervention: CTD0.02 (0.02 mg CTD/kg body weight)
Number of subjects: 24
Study 23358514 — intervention group
Group type: EXPERIMENTAL
Intervention: CTD1 (1 mg CTD/kg body weight)
Number of subjects: 24
Study 23358514 — intervention group
Group type: EXPERIMENTAL
Intervention: CTD50 (50 mg CTD/kg body weight)
Number of subjects: 24
Study 23358514 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg CTD/kg body weight)
Number of subjects: 24
Study 21289225 — intervention group
Group type: EXPERIMENTAL
Intervention: 85% energy density condition (with puréed vegetables)
Number of subjects: 41
Study 21289225 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% energy density condition (with puréed vegetables)
Number of subjects: 41
Study 21289225 — intervention group
Group type: COMPARATOR
Intervention: 100% energy density condition (standard version)
Number of subjects: 41
Study 19259838 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cultural competence course
Number of subjects: 122
Study 19259838 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 122
Study 16923699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized pentoxifylline (PTXF) 20 mg/kg (spontaneous breathing) or 10 mg/kg (ventilatory support) every 6 hours for 3 days
Number of subjects: 150
Study 16923699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (DX) 0.25 mg/kg every 12 hours for 3 days
Number of subjects: 150
Study 16923699 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nebulized distilled water)
Number of subjects: 150
Study 15059684 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 units of alcohol (4 UA: 32 g ethyl alcohol, 1203.8 kJ)
Number of subjects: 12
Study 15059684 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 unit of alcohol (1 UA: 8 g ethyl alcohol, 498.2 kJ)
Number of subjects: 12
Study 15059684 — intervention group
Group type: COMPARATOR
Intervention: No-alcohol lager (no-alcohol condition)
Number of subjects: 12
Study 15059684 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 units of alcohol (4 UA)
Number of subjects: 12
Study 15059684 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 unit of alcohol (1 UA)
Number of subjects: 12
Study 11157561 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyositis and dermatomyositis
Number of subjects: 0
Study 11157561 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion body myositis
Number of subjects: 0
Study 11157561 — intervention group
Group type: COMPARATOR
Intervention: Controls (muscular dystrophies)
Number of subjects: 0
Study 11157561 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflamed muscle
Number of subjects: 0
Study 11157561 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-1
Number of subjects: 0
Study 11157561 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-9
Number of subjects: 0
Study 11157561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera of affected patients
Number of subjects: 0
Study 10806670 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 48
Study 10806670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8167351 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan (16 mg/kg, n = 88)
Number of subjects: 167
Study 8167351 — intervention group
Group type: COMPARATOR
Intervention: Total Body Irradiation (TBI, n = 79)
Number of subjects: 167
Study 3048792 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201‐995 (Sandostatin)
Number of subjects: 16
Study 3048792 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin‐II (2‐10 ng/kg/min)
Number of subjects: 16
Study 30008188 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin + solifenacin
Number of subjects: 0
Study 30008188 — intervention group
Group type: COMPARATOR
Intervention: tamsulosin
Number of subjects: 0
Study 25642968 — intervention group
Group type: EXPERIMENTAL
Intervention: Early two-stage palatoplasty by the modified Furlow Technique (ETS)
Number of subjects: 71
Study 25642968 — intervention group
Group type: COMPARATOR
Intervention: One-stage Wardill-Kilner push-back palatoplasty (PB)
Number of subjects: 71
Study 25790835 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections at postoperative days 7 and 14
Number of subjects: 60
Study 25790835 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP injections)
Number of subjects: 60
Study 25790835 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP treatment
Number of subjects: 60
Study 23897968 — intervention group
Group type: EXPERIMENTAL
Intervention: PCE (paclitaxel/carboplatin + enzastaurin)
Number of subjects: 142
Study 23897968 — intervention group
Group type: COMPARATOR
Intervention: PC (paclitaxel/carboplatin + placebo)
Number of subjects: 142
Study 23897968 — intervention group
Group type: EXPERIMENTAL
Intervention: PCE
Number of subjects: 142
Study 23897968 — intervention group
Group type: COMPARATOR
Intervention: PC
Number of subjects: 142
Study 20420283 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal insert (10 mg for 12 hours)
Number of subjects: 200
Study 20420283 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (20 IU during cesarean delivery)
Number of subjects: 200
Study 18240245 — intervention group
Group type: EXPERIMENTAL
Intervention: PYD plus exercise
Number of subjects: 165
Study 18240245 — intervention group
Group type: EXPERIMENTAL
Intervention: PYD plus diet recall but no exercise
Number of subjects: 165
Study 18240245 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus exercise
Number of subjects: 165
Study 18240245 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus diet recall but no exercise
Number of subjects: 165
Study 18240245 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise groups (PYD plus exercise and placebo plus exercise)
Number of subjects: 165
Study 16803851 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (D2R agonist)
Number of subjects: 18
Study 14529100 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg
Number of subjects: 554
Study 14529100 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg
Number of subjects: 554
Study 14529100 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 180 microg
Number of subjects: 554
Study 14529100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study 10637064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin (50 mg/m²) plus intravenous epidoxorubicin (60 mg/m²) and intravenous cyclophosphamide (600 mg/m²)
Number of subjects: 113
Study 10637064 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cisplatin (50 mg/m²) plus intravenous epidoxorubicin (60 mg/m²) and intravenous cyclophosphamide (600 mg/m²)
Number of subjects: 113
Study 8892457 — intervention group
Group type: EXPERIMENTAL
Intervention: CY/TBI (120 mg/kg cyclophosphamide and 1320 cGy total body irradiation)
Number of subjects: 75
Study 8892457 — intervention group
Group type: EXPERIMENTAL
Intervention: BU/CY (16 mg/kg Busulfan and 200 mg/kg cyclophosphamide)
Number of subjects: 75
Study 8892457 — intervention group
Group type: EXPERIMENTAL
Intervention: CY/TBI
Number of subjects: 75
Study 8892457 — intervention group
Group type: EXPERIMENTAL
Intervention: BU/CY
Number of subjects: 75
Study 1647496 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg subcutaneous injection)
Number of subjects: 49
Study 1647496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 6607245 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant CMF (6 months)
Number of subjects: 0
Study 6607245 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose CMFVP
Number of subjects: 0
Study 6607245 — intervention group
Group type: EXPERIMENTAL
Intervention: Three drug combination CAF (doxorubicin)
Number of subjects: 0
Study 6607245 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF
Number of subjects: 0
Study 6607245 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMELEON (sequentially alternating therapy) added to CAF
Number of subjects: 0
Study 6607245 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive combination chemotherapeutic approaches
Number of subjects: 0
Study 30411521 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D interactive software for acetabular fracture classification
Number of subjects: 30
Study 30411521 — intervention group
Group type: COMPARATOR
Intervention: Traditional 2D tutorial for acetabular fracture classification
Number of subjects: 30
Study 29766633 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 2.5 mg
Number of subjects: 48
Study 29766633 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 48
Study 29766633 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 48
Study 29766633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 26694940 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsalis pedis artery (DPA)
Number of subjects: 37
Study 24065729 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 12
Study 24065729 — intervention group
Group type: COMPARATOR
Intervention: Online-based training
Number of subjects: 12
Study 24065729 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (simulation and online)
Number of subjects: 12
Study 22197080 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 58
Study 22197080 — intervention group
Group type: COMPARATOR
Intervention: Conventional Vocational Rehabilitation (CVR)
Number of subjects: 58
Study 19779730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy at sclerotomy sites (two spots at each site)
Number of subjects: 88
Study 19779730 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 88
Study 19779730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy at sclerotomy sites
Number of subjects: 88
Study 17490659 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens (red clover and soy)
Number of subjects: 0
Study 17490659 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens
Number of subjects: 0
Study 15535111 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 45
Study 15535111 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine
Number of subjects: 45
Study 11275859 — intervention group
Group type: COMPARATOR
Intervention: Standard care (ice, elevation, and immobilization)
Number of subjects: 77
Study 11275859 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care and ibuprofen
Number of subjects: 77
Study 11275859 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care and music distraction
Number of subjects: 77
Study 11275859 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 77
Study 11275859 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pain ratings
Number of subjects: 77
Study 9675382 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 1 mg.kg‐1 + 200 micrograms.kg‐1.min‐1
Number of subjects: 40
Study 9675382 — intervention group
Group type: COMPARATOR
Intervention: saline (control group)
Number of subjects: 40
Study 7989509 — intervention group
Group type: EXPERIMENTAL
Intervention: Teratozoospermic group (T)
Number of subjects: 68
Study 7989509 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 68
Study 2660557 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g three times a day
Number of subjects: 500
Study 2660557 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice a day
Number of subjects: 500
Study 7816004 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice with K+ (35 mmol), Mg2+ (17 mmol), and HPO4(2‐) (39 mmol)
Number of subjects: 30
Study 7816004 — intervention group
Group type: COMPARATOR
Intervention: Orange juice only (without K- and Mg-phosphate supplementation)
Number of subjects: 30
Study 7816004 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice with K- and Mg-phosphate supplementation
Number of subjects: 30
Study 391578 — intervention group
Group type: EXPERIMENTAL
Intervention: tienilic acid
Number of subjects: 56
Study 391578 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide
Number of subjects: 56
Study 30093119 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading
Number of subjects: 15
Study 30093119 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading
Number of subjects: 15
Study 30093119 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study 28240625 — intervention group
Group type: EXPERIMENTAL
Intervention: In SHAPE program (gym membership, weekly individual meetings with a fitness trainer, instruction on healthy eating and nutrition)
Number of subjects: 343
Study 28240625 — intervention group
Group type: EXPERIMENTAL
Intervention: In SHAPE program
Number of subjects: 343
Study 28240625 — intervention group
Group type: COMPARATOR
Intervention: Gym membership control condition
Number of subjects: 343
Study 25648347 — intervention group
Group type: EXPERIMENTAL
Intervention: FMI tablet (500 mg)
Number of subjects: 63
Study 25648347 — intervention group
Group type: COMPARATOR
Intervention: HF meal (with FMI tablet 300 mg)
Number of subjects: 63
Study 25648347 — intervention group
Group type: COMPARATOR
Intervention: LF meal (with FMI tablet 300 mg)
Number of subjects: 63
Study 25648347 — intervention group
Group type: COMPARATOR
Intervention: NM (with FMI tablet 300 mg)
Number of subjects: 63
Study 24463669 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg once daily during catheterization
Number of subjects: 159
Study 24463669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 20922510 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Project intervention (five-session, individually delivered coping skills intervention)
Number of subjects: 249
Study 20922510 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 249
Study 19620077 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy at 3.0 Gy/fraction (30 Gy total) combined with weekly docetaxel at 60 mg for 2 weeks
Number of subjects: 72
Study 19620077 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone at 2.0 Gy/fraction (40 Gy total)
Number of subjects: 72
Study 19620077 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 72
Study 17517703 — intervention group
Group type: EXPERIMENTAL
Intervention: BF‐1 fermented milk
Number of subjects: 79
Study 17517703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 15363024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural and Self‐Empowerment Group
Number of subjects: 15
Study 15363024 — intervention group
Group type: COMPARATOR
Intervention: Modified Cultural Group
Number of subjects: 15
Study 15363024 — intervention group
Group type: COMPARATOR
Intervention: Traditional Group
Number of subjects: 15
Study 11474385 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine sedation with midazolam (0.07 mg/kg) and meperidine (0.77 mg/kg)
Number of subjects: 249
Study 11474385 — intervention group
Group type: COMPARATOR
Intervention: On demand sedation with midazolam and meperidine
Number of subjects: 249
Study 11474385 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine sedation with midazolam and meperidine
Number of subjects: 249
Study 9924308 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOLs
Number of subjects: 90
Study 9924308 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA IOLs
Number of subjects: 90
Study 9924308 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylic IOLs
Number of subjects: 90
Study 9924308 — intervention group
Group type: COMPARATOR
Intervention: Control group (PMMA and silicone IOLs)
Number of subjects: 90
Study 8055491 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation and visualization training
Number of subjects: 24
Study 8055491 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation, visualization, and cognitive coping skills training
Number of subjects: 24
Study 8055491 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 3291895 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine 30 mg po
Number of subjects: 11
Study 3291895 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 31538488 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention (6-weekly visits from a peer support worker in addition to routine care)
Number of subjects: 20
Study 31538488 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care alone including contact with a midwife and access to a GP if required)
Number of subjects: 20
Study 31679018 — intervention group
Group type: EXPERIMENTAL
Intervention: High-heat capacity mattress
Number of subjects: 0
Study 31679018 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-heat capacity mattress
Number of subjects: 0
Study 26482148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cherry juice (200 ml/day)
Number of subjects: 49
Study 26482148 — intervention group
Group type: COMPARATOR
Intervention: Control juice (negligible anthocyanin content)
Number of subjects: 49
Study 26289448 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency telephone-delivered lifestyle support (10 times)
Number of subjects: 2607
Study 26289448 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency telephone-delivered lifestyle support (3 times)
Number of subjects: 2607
Study 26289448 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-frequency telephone-delivered lifestyle support (6 times)
Number of subjects: 2607
Study 26289448 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 2607
Study 24013186 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamicastat
Number of subjects: 8
Study 24013186 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant NAT1 and NAT2 enzymes
Number of subjects: 8
Study 24013186 — intervention group
Group type: EXPERIMENTAL
Intervention: Human single-donor enzymes
Number of subjects: 8
Study 24013186 — intervention group
Group type: COMPARATOR
Intervention: p-aminosalicylic acid
Number of subjects: 8
Study 22290680 — intervention group
Group type: EXPERIMENTAL
Intervention: iv lornoxicam (8 mg)
Number of subjects: 60
Study 22290680 — intervention group
Group type: EXPERIMENTAL
Intervention: iv paracetamol (1 g)
Number of subjects: 60
Study 22290680 — intervention group
Group type: COMPARATOR
Intervention: iv saline solution (Control)
Number of subjects: 60
Study 19597368 — intervention group
Group type: EXPERIMENTAL
Intervention: P-OM3 + FENO (4 g QD + 130 mg QD)
Number of subjects: 163
Study 19597368 — intervention group
Group type: COMPARATOR
Intervention: FENO (130 mg QD)
Number of subjects: 163
Study 19597368 — intervention group
Group type: EXPERIMENTAL
Intervention: P-OM3 added to FENO monotherapy during open-label extension
Number of subjects: 163
Study 19597368 — intervention group
Group type: EXPERIMENTAL
Intervention: P-OM3 + FENO in second open-label extension
Number of subjects: 163
Study 16716211 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group (two 45 minute walks per week)
Number of subjects: 37
Study 16716211 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 37
Study 15575109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise program with a refrigerator magnet education tool
Number of subjects: 0
Study 15575109 — intervention group
Group type: COMPARATOR
Intervention: Paper copy education tool
Number of subjects: 0
Study 10980880 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic anticoagulation therapy
Number of subjects: 0
Study 10980880 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 9001369 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation
Number of subjects: 122
Study 9001369 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented children
Number of subjects: 122